Skip to main content

L-dihydroxyphenylserine (Droxidopa) in the treatment of orthostatic hypotension

The European experience


Neurogenic orthostatic hypotension is a cardinal feature of generalised autonomic failure and commonly is the presenting sign in patients with primary autonomic failure. Orthostatic hypotension can result in considerable morbidity and even mortality and is a major management problem in disorders such as pure autonomic failure, multiple system atrophy and also in Parkinson’s disease. Treatment is ideally two pronged, using non-pharmacological and pharmacological measures.

Drug treatment ideally is aimed at restoring adequate amounts of the neurotransmitter noradrenaline. This often is not achievable because of damage to sympathetic nerve terminals, to autonomic ganglia or to central autonomic networks. An alternative is the use of sympathomimetics (that mimic the effects of noradrenaline, but are not identical to noradrenaline), in addition to other agents that target physiological mechanisms that contribute to blood pressure control.

L-threo-dihydroxyphenyslerine (Droxidopa) is a pro-drug which has a structure similar to noradrenaline, but with a carboxyl group. It has no pressor effects in this form. It can be administered orally, unlike noradrenaline, and after absorption is converted by the enzyme dopa decarboxylase into noradrenaline thus increasing levels of the neurotransmitter which is identical to endogenous noradrenaline. Experience in Caucasians and in Europe is limited mainly to patients with dopamine beta hydroxylase deficiency. This review focuses on two studies performed in Europe, and provides information on its efficacy, tolerability and safety in patients with pure autonomic failure, multiple system atrophy and Parkinson’s disease. It also addresses the issue of whether addition of dopa decarboxylase inhibitors, when combined with l-dopa in the treatment of the motor deficit in Parkinson’s disease, impairs the pressor efficacy of Droxidopa.

This is a preview of subscription content, access via your institution.

Fig. 1
Fig. 2


  1. Heims HC, Martin NH, Critchley HD, Jäger HR, Mathias CJ, Cipolotti L. (2006). Cognitive functioning in orthostatic hypotension due to pure autonomic failure. Clin Aut Res 16:113–120

    Article  Google Scholar 

  2. Kaufmann H, Saadia D, Voustianiouk A, Goldstein DS, Holmes C, Yahr MD, Nardin R, Freeman R. (2003) Norepinephrine precursor therapy in neurogenic orthostatic hypotension. Circulation. 108:724–728

    PubMed  Article  CAS  Google Scholar 

  3. Lahrmann H, Cortelli, Hilz M, Mathias CJ, Struhal W, Tassinari M. (2006) European Federation of Neurological Society guidelines on the diagnosis and management of orthostatic hypotension. Europ J Neurol 13:930–6

  4. Man in’t Veld AJ, Van den Meiracker AH, Boomsma F, Schalekamp MADH. (1987) Effect of unnatural noradrenaline precursor on sympathetic control and orthostatic hypotension in dopamine beta-hydroxylase deficiency. Lancet ii:1172–5

    Google Scholar 

  5. Mathias CJ, Bannister R, Cortelli P, Heslop K, Polak J, Raimbach SJ, Springall DB, Watson L. (1990) Clinical autonomic and therapeutic observations in two siblings with postural hypotension and sympathetic failure due to an inability to synthesize noradrenaline from dopamine because of a deficiency of dopamine beta-hydroxylase. QJM, New Series 75(278):617–633

    CAS  Google Scholar 

  6. Mathias CJ, Mallipeddi R, Bleasdale-Barr K. (1999) Symptoms associated with orthostatic hypotension in pure autonomic failure and multiple system atrophy. J Neurol 246(10):893–898

    PubMed  Article  CAS  Google Scholar 

  7. Mathias CJ, Senard J-M, Braune S, Watson L, Aragishi A, Keeling J, Taylor M. (2001) L-threo-dihydroxphenylserine (L-threo-DOPS; droxidopa) in the management of neurogenic orthostatic hypotension: a multi-national, multi-centre, dose-ranging study in multiple system atrophy and pure autonomic failure. Clin Aut Res 11:235–242

    Article  CAS  Google Scholar 

  8. Mathias CJ, Bannister R. (2002) Dopamine beta-hydroxylase deficiency. In: Mathias CJ, Bannister R, (eds.) Autonomic failure. A textbook of clinical disorders of the autonomic nervous system. 4th ed. Oxford and New York: Oxford University Press pp. 387–401

    Google Scholar 

  9. Mathias CJ. (2003) Autonomic diseases – clinical features and laboratory evaluation. JNNP 74:31–41

    Google Scholar 

  10. Mathias CJ. (2003) Autonomic diseases – Management. JNNP 74:42–47

    Google Scholar 

  11. Mathias CJ. (2005) Cardiovascular Autonomic Dysfunction in Parkinson’s Disease and Parkinsonian Syndromes. In: Ebadi M, Pfeiffer RF. (Eds.) Parkinson’s Disease. CRC Press LLC, New York 295–317

    Google Scholar 

  12. Mathias CJ. (2006) Orthostatic hypotension and orthostatic intolerance. In: DeGroot LJ, Jameson JL, de Kretser D, Grossman AB, Marshall JC, Melmed S, Potts JT, Weir GC. (Eds.) Endocrinology. 5th edition. Elsevier Saunders, Philadelphia PA, USA 2613–2632

    Google Scholar 

  13. Mathias CJ, Senard JM, Cortelli P. (2007) A double-blind, randomized, placebo-controlled study to determine the efficacy and safety of droxidopa in the treatment of orthostatic hypotension associated with multiple system atrophy or Parkinson’s disease. Clin Aut Res 17:272. abstract

    Google Scholar 

  14. Narabayashi H, Nakanishi T. (1987) Therapeutic effects of L-DOPS in Parkinson’s disease, double-blind comparative study against placebo as control in patients with long-term levodopa therapy. Clin Eva1 15:423–457

    Google Scholar 

  15. Robertson D, Goldberg MR, Onrot J, Hollister AS, Wiley R, Thompson JG, Robertson RM. (1987) Isolated failure of autonomic noradrenergic neurotransmission. Evidence for impaired beta-hydroxylation of dopamine New Engl. J. Med 314:1494–7

    Article  Google Scholar 

  16. Sobue I, Senda Y, Hirayama K, et al. (1987) Clinical pharmacological evaluation of L-threo-3-4-dihydroxyphenylserine (L-DOPS) in Shy-Drager’s syndrome and its related diseases. A nationwide double-blind comparative study. Jpn J Clin Exp Med 141:353–378

    Google Scholar 

  17. Suzuki T, Higa S, Sakoda S, et al. (1982) Pharmacokinetic studies of oral L-threo-3,4-dihydroxyphenylserine in normal subjects and patients with familial amyloid polyneuropathy. Eur J Clin Pharmacol 23:463–468

    PubMed  Article  CAS  Google Scholar 

  18. Yanagisawa N, Ikeda S, Hashimoto T, Hanyu N, Nakagawa S, Fujimori N, Ushiyama M. (1998) Effects of L-threo-Dops on orthostatic hypotension in Parkinson’s disease. No To Shinkei 50:157–63

    PubMed  CAS  Google Scholar 

Download references


Major investigators have included Professor P Cortelli, Professor J M Senard, and many colleagues in participating centres. Disclosure Prof. C.J. Mathias was the Principal Investigator of both studies reviewed, which were supported by Sumitomo Pharmaceuticals, Japan. He is a Consultant for Chelsea Therapeutics, USA.

Author information

Authors and Affiliations


Corresponding author

Correspondence to Christopher J. Mathias DPhil, DSc, FRCP, FMedSci.

Rights and permissions

Reprints and Permissions

About this article

Cite this article

Mathias, C.J. L-dihydroxyphenylserine (Droxidopa) in the treatment of orthostatic hypotension. Clin Auton Res 18, 25–29 (2008).

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI:

Key words

  • l-dihydroxyphenylserine
  • orthostatic hypotension
  • autonomic failure
  • noradrenaline
  • multiple system atrophy
  • Parkinson's disease